Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
Henan Provincial and Zhengzhou City Key laboratory of Non-coding RNA and Cancer Metabolism, Henan International Join Laboratory of Non-coding RNA and Metabolism in Cancer, People's Hospital of Zhengzhou University, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, 450053, China.
Adv Sci (Weinh). 2022 Oct;9(30):e2201210. doi: 10.1002/advs.202201210. Epub 2022 Sep 1.
Glucose metabolism contributes to DNA damage response pathways by regulating chromatin remodeling, double-strand break (DSB) repair, and redox homeostasis, although the underlying mechanisms are not fully established. Here, a previously uncharacterized long non-coding RNA is revealed that is call Vanguard which acts to promote HMGB1-dependent DNA repair in association with changes in global chromatin accessibility. Vanguard expression is maintained in cancer cells by SP1-dependent transcription according to glucose availability and cellular adenosine triphosphate (ATP) levels. Vanguard promotes complex formation between HMGB1 and HDAC1, with the resulting deacetylation of HMGB1 serving to maintain its nuclear localization and DSB repair function. However, Vanguard downregulation under glucose limiting conditions promotes HMGB1 translocation from the nucleus, increasing DNA damage, and compromising cancer cell growth and viability. Moreover, Vanguard silencing increases the effectiveness of poly (ADP-ribose) polymerase inhibitors against breast cancer cells with wild-type breast cancer gene-1 status, suggesting Vanguard as a potential therapeutic target.
葡萄糖代谢通过调节染色质重塑、双链断裂 (DSB) 修复和氧化还原稳态来参与 DNA 损伤反应途径,尽管其潜在机制尚未完全确定。在这里,揭示了一种以前未被表征的长非编码 RNA,称为 Vanguard,它通过与全局染色质可及性变化相关联,促进 HMGB1 依赖性 DNA 修复。根据葡萄糖的可用性和细胞三磷酸腺苷 (ATP) 水平,SP1 依赖性转录维持癌细胞中 Vanguard 的表达。Vanguard 促进 HMGB1 和 HDAC1 之间形成复合物,导致 HMGB1 的去乙酰化有助于维持其核定位和 DSB 修复功能。然而,在葡萄糖限制条件下下调 Vanguard 会促进 HMGB1 从核内易位,增加 DNA 损伤,并损害癌细胞的生长和活力。此外,沉默 Vanguard 会增加聚 (ADP-核糖) 聚合酶抑制剂对具有野生型乳腺癌基因-1 状态的乳腺癌细胞的有效性,这表明 Vanguard 是一个潜在的治疗靶点。